SynaptixBio: Rare Disease Biotech Investment Rising in US After PRV Renewal, UK Lagging Behind

Investment in US rare disease biotech has increased following the FDA's Priority Review Voucher (PRV) program renewal, while UK rare disease companies lack a similar incentive and face funding challenges. The UK's MHRA is consulting on faster regulatory frameworks, but industry leaders suggest a PRV-like incentive is needed to boost UK biotech investment and competitiveness.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.